glufosfamide
Small moleculeexperimental
Glufosfamide, also known as glucophosphamide, D-glucose isophosphoramide mustard, D-19575 is an experimental cytotoxic chemotherapeutic agent for treatment of malignancies. — Wikipedia
Clinical trial activity
9 trials · 22 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
9
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 1999 (NCT00005053)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O- Mol. weight
- 383.17 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGlufosfamide ↗
- ChEMBLCHEMBL2107143 ↗
Also known as
- beta-d-glc-ipm
- beta-d-glucosyl-ifosfamide mustard
- beta-d-glucosylisophosphoramide mustard
- d 19575
- d-19575
- glucosyl-ifosfamide mustard
- glufosfamide
- glufosfamide
- glufosfamide
- glufosfamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01954992 | Phase 3 | Sep 1, 2013 | Eleison Pharmaceuticals |
| NCT00441467 | Phase 2 | Mar 1, 2007 | Eleison Pharmaceuticals, New York Medical College, Premiere Oncology, Stanford University, Threshold Pharmaceuticals, University of Arizona, University of New Mexico, University of South Florida, Washington University in St. Louis |
| NCT00435578 | Phase 2 | Feb 1, 2007 | California Cancer Center, Threshold Pharmaceuticals, University of South Florida, Wayne State University |
| NCT00442598 | Phase 2 | Jan 1, 2007 | California Cancer Center, Eleison Pharmaceuticals, Gabrail Cancer Center, Harrington Cancer Center, Indiana University, New Mexico Cancer Care Alliance, Premiere Oncology, University of Arizona, University of California, Irvine, University of Louisville |
| NCT00102752 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2004 | PPD, Threshold Pharmaceuticals |
| NCT00099294 | Phase 3 | Sep 1, 2004 | PPD, Threshold Pharmaceuticals |
| NCT00014300 | Phase 2 | Jan 1, 2001 | Erasmus University Rotterdam, European Organisation for Research and Treatment of Cancer |
| NCT00005055 | Phase 2 | Jan 1, 2000 | Centre Georges Francois Leclerc, European Organisation for Research and Treatment of Cancer |
| NCT00005053 | Phase 2 | Dec 1, 1999 | European Organisation for Research and Treatment of Cancer, University of Ioannina |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (22)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Threshold Pharmaceuticals | For profit | 4 | 3 | 2 | 2004 |
| Eleison Pharmaceuticals | For profit | 3 | 3 | 2 | 2007 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 3 | 3 | 1 | 1999 |
| California Cancer Center | Academic/Hospital | 2 | 0 | 1 | 2007 |
| PPD | For profit | 2 | 0 | 2 | 2004 |
| Premiere Oncology | For profit | 2 | 0 | 1 | 2007 |
| University of Arizona | Academic/Hospital | 2 | 0 | 1 | 2007 |
| University of South Florida | Academic/Hospital | 2 | 0 | 1 | 2007 |
| Centre Georges Francois Leclerc | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Gabrail Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Harrington Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| New Mexico Cancer Care Alliance | Academic/Hospital | 1 | 0 | 1 | 2007 |
| New York Medical College | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of California, Irvine | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Ioannina | Academic/Hospital | 1 | 0 | 1 | 1999 |
| University of Louisville | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of New Mexico | Academic/Hospital | 1 | 0 | 1 | 2007 |
22 organizations
Page 1 / 2